8-KLeadership ChangesShareholder MattersExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Executive Changes (Jun 5, 2024)

Filed June 5, 2024For Securities:ONCBEIGF

Summary

BeiGene, Ltd. (ONC) filed an 8-K on June 5, 2024, detailing the outcomes of its 2024 Annual General Meeting of Shareholders. The most significant investor-focused updates involve the shareholder approval of amendments to key equity incentive plans. Specifically, the Third Amended and Restated 2016 Share Option and Incentive Plan and the Fourth Amended and Restated 2018 Employee Share Purchase Plan were approved. These amendments, driven by changes in Hong Kong Listing Rules, include substantial increases in the number of shares available for issuance under these plans. The former plan now has an additional 92,820,000 shares available, while the latter has an additional 5,070,000 shares available. Furthermore, the meeting saw the re-election of several Class II directors, including Dr. Olivier Brandicourt, Mr. Donald W. Glazer, Mr. Michael Goller, and Dr. Corazon (Corsee) D. Sanders, all approved by significant margins. The company also received shareholder approval for a general mandate to issue up to 20% of its outstanding shares and a mandate to repurchase up to 10% of its outstanding shares, providing flexibility for capital management. Additionally, significant grants of Restricted Share Units (RSUs) and Performance Share Units (PSUs) to named executive officers, including CEO John V. Oyler and Dr. Xiaodong Wang, were approved, along with advisory votes on executive compensation and the frequency of future say-on-pay votes, which will be held annually.

Key Highlights

  • 1Shareholders approved the Third Amended and Restated 2016 Share Option and Incentive Plan, increasing the share pool by 92,820,000 shares.
  • 2Shareholders approved the Fourth Amended and Restated 2018 Employee Share Purchase Plan, increasing the share pool by 5,070,000 shares.
  • 3Dr. Olivier Brandicourt, Mr. Donald W. Glazer, Mr. Michael Goller, and Dr. Corazon (Corsee) D. Sanders were re-elected as Class II directors.
  • 4A general mandate was approved, allowing the Board to issue up to 20% of outstanding shares.
  • 5A general mandate was approved, allowing the Board to repurchase up to 10% of outstanding shares.
  • 6Shareholder approval was granted for significant RSU and PSU grants to executive officers, including CEO John V. Oyler and Dr. Xiaodong Wang.
  • 7An advisory vote on named executive officer compensation was approved, and shareholders voted for annual 'say-on-pay' votes.

Frequently Asked Questions

The primary purposes of the amendments are to comply with certain changes in the Hong Kong Listing Rules and to increase the number of shares available for issuance and sale under these plans, thereby providing the company with greater flexibility for employee compensation and equity-based incentives.

The 2016 Share Option and Incentive Plan's share pool is increased by 92,820,000 shares, and the 2018 Employee Share Purchase Plan's share pool is increased by 5,070,000 shares.

Yes, the shareholders approved substantial grants of Restricted Share Units (RSUs) and Performance Share Units (PSUs) to named executive officers, including grants valued at US$6,000,000 in RSUs and US$6,000,000 in PSUs to CEO John V. Oyler, and grants valued at US$1,333,333 in RSUs to Dr. Xiaodong Wang. Additionally, RSUs were approved for independent non-executive directors.

The approval of a general mandate for the Board to issue up to 20% of outstanding shares and to repurchase up to 10% of outstanding shares provides BeiGene with significant flexibility in managing its capital structure, potentially for future financing, acquisitions, or share buyback programs.